Cargando…

Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020

BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strate...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakalle, Salil, Saroshe, Satish, Shukla, Harish, Mutha, Anita, Vaze, Ameya, Arora, Arpit, Athotra, Aditya, Ramaswamy, Sudarshan, Jain, Arania, Dhuria, Meera, Patil, Anil D., Rai, Arvind, Garg, Suneela, Jain, Sudhir K., Bindal, Jyoti, Singh, Sujeet K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140269/
https://www.ncbi.nlm.nih.gov/pubmed/34041197
http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20
_version_ 1783696158604918784
author Sakalle, Salil
Saroshe, Satish
Shukla, Harish
Mutha, Anita
Vaze, Ameya
Arora, Arpit
Athotra, Aditya
Ramaswamy, Sudarshan
Jain, Arania
Dhuria, Meera
Patil, Anil D.
Rai, Arvind
Garg, Suneela
Jain, Sudhir K.
Bindal, Jyoti
Singh, Sujeet K.
author_facet Sakalle, Salil
Saroshe, Satish
Shukla, Harish
Mutha, Anita
Vaze, Ameya
Arora, Arpit
Athotra, Aditya
Ramaswamy, Sudarshan
Jain, Arania
Dhuria, Meera
Patil, Anil D.
Rai, Arvind
Garg, Suneela
Jain, Sudhir K.
Bindal, Jyoti
Singh, Sujeet K.
author_sort Sakalle, Salil
collection PubMed
description BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strategies. Exact estimate is difficult under high-risk screening strategy with evidences of having large number of asymptomatic cases. This has prompted a call for adoption of antibody testing as potential source of data. MATERIALS AND METHODS: A cross-sectional study with a sample size of 7000 was conducted for 15 days including all the 85 wards under Indore Municipal Corporation. Stratified Random Sampling was used to collect the samples. Trained teams collected basic sociodemographic information and serum samples which were tested for the presence of specific antibodies to COVID-19 using ICMR-Kavach IgG ELISA kits. The data collected was compiled and analysed using appropriate statistical software. RESULTS: Overall weighted seroprevalence of the study population was found to be 7.75%. The prevalence in males and females was comparable (7.91% vs 7.57%). Highest seropositivity (10.04%) was seen among individuals aged more than 60 years. Total number of infections in the population were estimated to be 2,03,160. Overall Case Infection Ratio was found to be 27.43. CONCLUSION: The current seroprevalence study provides information on proportion of the population exposed, but the correlation between presence and absence of antibodies is not a marker of total or partial immunity. It must also be noted that more than 90 percent of the population is still susceptible for COVID-19 infection. Hence, non-pharmaceutical interventions like respiratory hygiene, physical distancing, hand sanitization, usage of personal protective equipment such as masks and implementation of public health measures need to be continued.
format Online
Article
Text
id pubmed-8140269
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81402692021-05-25 Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020 Sakalle, Salil Saroshe, Satish Shukla, Harish Mutha, Anita Vaze, Ameya Arora, Arpit Athotra, Aditya Ramaswamy, Sudarshan Jain, Arania Dhuria, Meera Patil, Anil D. Rai, Arvind Garg, Suneela Jain, Sudhir K. Bindal, Jyoti Singh, Sujeet K. J Family Med Prim Care Original Article BACKGROUND: In India, laboratory diagnosis of SARS – CoV-2 infection has been mostly based on real-time reverse transcriptase-polymerase chain reaction (RT-PCR). Studies have shown that Viral titres peak within the first week of symptoms but may decline later hampering RT-PCR-based diagnostic strategies. Exact estimate is difficult under high-risk screening strategy with evidences of having large number of asymptomatic cases. This has prompted a call for adoption of antibody testing as potential source of data. MATERIALS AND METHODS: A cross-sectional study with a sample size of 7000 was conducted for 15 days including all the 85 wards under Indore Municipal Corporation. Stratified Random Sampling was used to collect the samples. Trained teams collected basic sociodemographic information and serum samples which were tested for the presence of specific antibodies to COVID-19 using ICMR-Kavach IgG ELISA kits. The data collected was compiled and analysed using appropriate statistical software. RESULTS: Overall weighted seroprevalence of the study population was found to be 7.75%. The prevalence in males and females was comparable (7.91% vs 7.57%). Highest seropositivity (10.04%) was seen among individuals aged more than 60 years. Total number of infections in the population were estimated to be 2,03,160. Overall Case Infection Ratio was found to be 27.43. CONCLUSION: The current seroprevalence study provides information on proportion of the population exposed, but the correlation between presence and absence of antibodies is not a marker of total or partial immunity. It must also be noted that more than 90 percent of the population is still susceptible for COVID-19 infection. Hence, non-pharmaceutical interventions like respiratory hygiene, physical distancing, hand sanitization, usage of personal protective equipment such as masks and implementation of public health measures need to be continued. Wolters Kluwer - Medknow 2021-03 2021-04-08 /pmc/articles/PMC8140269/ /pubmed/34041197 http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20 Text en Copyright: © 2021 Journal of Family Medicine and Primary Care https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Sakalle, Salil
Saroshe, Satish
Shukla, Harish
Mutha, Anita
Vaze, Ameya
Arora, Arpit
Athotra, Aditya
Ramaswamy, Sudarshan
Jain, Arania
Dhuria, Meera
Patil, Anil D.
Rai, Arvind
Garg, Suneela
Jain, Sudhir K.
Bindal, Jyoti
Singh, Sujeet K.
Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title_full Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title_fullStr Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title_full_unstemmed Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title_short Seroprevalence of anti-SARS-CoV-2 antibodies in Indore, Madhya Pradesh: A community-based cross-sectional study, August 2020
title_sort seroprevalence of anti-sars-cov-2 antibodies in indore, madhya pradesh: a community-based cross-sectional study, august 2020
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8140269/
https://www.ncbi.nlm.nih.gov/pubmed/34041197
http://dx.doi.org/10.4103/jfmpc.jfmpc_2015_20
work_keys_str_mv AT sakallesalil seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT saroshesatish seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT shuklaharish seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT muthaanita seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT vazeameya seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT aroraarpit seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT athotraaditya seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT ramaswamysudarshan seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT jainarania seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT dhuriameera seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT patilanild seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT raiarvind seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT gargsuneela seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT jainsudhirk seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT bindaljyoti seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020
AT singhsujeetk seroprevalenceofantisarscov2antibodiesinindoremadhyapradeshacommunitybasedcrosssectionalstudyaugust2020